NCT02889068
Completed
Not Applicable
Targeted Next Generation Sequencing and Intellectual Disability
Central Hospital, Nancy, France1 site in 1 country40 target enrollmentJuly 2015
ConditionsIntellectual Disability
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Intellectual Disability
- Sponsor
- Central Hospital, Nancy, France
- Enrollment
- 40
- Locations
- 1
- Primary Endpoint
- Percentage of patients with certain etiologic diagnosis established with NGS
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
The purpose is to determine the benefit of next generation sequencing (NGS) targeted on genes involved in intellectual disability for etiologic diagnosis of intellectual disabilities. In other words, it concerns the number of patients whose etiologic diagnosis will be established with NGS and could not with common techniques. Actually, the molecular etiology of intellectual disability is crucial to calculate the risk of recurrence and allows the perinatal diagnosis to these families.
Secondary purposes are:
- To determine the place of NGS in the strategy of etiologic diagnosis of intellectual disability, to determine the order of analyses performed for a patient with intellectual disability without clinical signs.
- To evaluate the number of variants with unknown significance and thus non-usable for genetic counselling without supplementary analysis.
- To determine the number of samples that can be at most pooled keeping a good efficacy of capture and results with suitable read depth
- To determine the possibility of detecting copy number variations (CNVs) in genes of interest with NGS
- To establish genotype/phenotype correlations for each gene for which a mutation has been identified
- To optimize the software pipelining for a rapid analysis for diagnosis.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Moderate or severe intellectual disability
- •Availability of patient and parent DNA
- •No etiologic diagnosis with standard approaches: negative fragile X, normal pangenomic 180K and 1M array-CGH
- •Informed consent of person having parental authority
Exclusion Criteria
- •Non availability of parent DNA
- •Patient lost to follow-up
Outcomes
Primary Outcomes
Percentage of patients with certain etiologic diagnosis established with NGS
Time Frame: day 0
Secondary Outcomes
- Percentage of patients with etiologic diagnosis established with NGS or with other techniques (array-CGH)(day 0)
- Obtained read depth according to number of pooled samples(day 0)
- Percentage of patients with variant with unknown significance, needing supplementary analyses to prove its involvement in intellectual disability(day 0)
- CNVs detected with NGS or array-CGH (reference technique for CNV detection).(day 0)
- Clinical phenotype for each gene for which a causal mutation is identified by NGS(day 0)
- Time of analysis of NGS raw data(day 0)
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Not Applicable
Genomic Sequencing and Personalized Treatment for Birth Defects in Neonatal Intensive Care UnitsGenetic DiseaseMultiple MalformationCongenital MalformationNCT02551081Children's Hospital of Fudan University2,000
Unknown
Not Applicable
Next Generation Sequencing(NGS)Monitors Minimal Residual Disease(MRD)in Allo-PBSCT PatientsNGS Monitor MRDNCT04126967Xianmin Song, MD100
Unknown
Not Applicable
NGS for Non-unionsNonunion of FractureNCT03937310Rothman Institute Orthopaedics120
Unknown
Not Applicable
Identifying Genomic Mutations of Multiple Primary Lung Cancers by Circulating Tumor DNACarcinomaNon-small-cell Lung CancerThoracic NeoplasmsNCT02833467Peking University People's Hospital45
Completed
Not Applicable
Next Generation to Identify Genetic Causes of Disease in Patients Participating in NICHD Clinical ProtocolsGenetic PredispositionNCT01375543Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)128